Shares in NZX-listed AFT Pharmaceuticals have risen 3% today after the US FDA approved the sale of its flagship pain relief product Maxigesic into that market, which the company says is worth US$6.83 billion.
It is the second FDA approval the Auckland-based pharmaceutical company has received this
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
